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Abstract
Thelkey to the successful treatment of myelodysplastic syndrome is the careful characterization and diagnosis of the disease, 
which includes clinical, cytogenetic, biological and molecular investigation of individual patients. Today therapeutic approaches to 
the treatment of such patients are differentiated and depend, first of all, on the subtype of the disease, age, general condition of the 
patients and the possibility of allogeneic hematopoietic cell transplantation. For young patients, the best option is transplantation, 
whereas in older patients, the standard of therapy is the use of hypomethylating agents (azacitidine, decitabine). These drugs promote 
hematologic improvement, elimination of transfusion dependence and prolongation of the duration of both general and leukemia free 
survival in elderly patients with concomitant pathology.
Despite the fact that therapy with hypomethylating drugs is widely used and has good results, many respondents are los-
ing their response within 1–2 years. Reasons for the development of resistance to this type of treatment are still unclear, and the 
insensitivity to drugs is associated with very poor prognosis in patients with all subtypes of myelodysplastic syndrome. Such data 
and the presence of numerous genetic and epigenetic mechanisms for the development of this pathology have prompted the use of 
combinations of drugs with different application points and are relevant in terms of research. In the literature review, the results of 
clinical studies on the use of hypomethylating agents in patients with MDS of low and high risk, as in monotherapy and combined 
schemes are presented.
The nearest prospect of treatment of myelodysplastic syndrome is the creation of new treatment regimens based on a combi-
nation of drugs of different pathogenetic direction for the elimination of the dysplastic clone in order to achieve not only long-term 
remissions, but also lengthening the duration of overall survival, especially for patients with high risk myelodysplastic syndrome.
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1. Introduction
Despite the long history of seeking therapeutic approaches to treatment of myelodysplastic 
syndrome (MDS), many aspects of this problem have not been resolved, some of them contradicto-
ry and, unfortunately, at present, the complete cure of this pathology for most patients remains im-
possible not only in Ukraine, but also in developed countries of the world. Scientists are convinced 
that the only radical method of treating this disease, for today, is the allogeneic hematopoietic cell 
transplantation (HTC). However, the problem with the presence an HLA- compatible donor makes 
this procedure far from being a routine practice and can only be used in 10 % of patients.
As noted at the 57th Congress of ASH, over the past 10 years, considerable progress has 
been made in the study of the pathogenesis of MDS, however, no significant progress has been 
made in the therapeutic approaches of individual MDS subtypes. Until recently, only substitution 
therapy used in such patients was hemotransfusion, which for some time improves the well-being 
of the patient, however, due to the development of transfusion dependence with clinical manifesta-
tions of iron overload, it is become the most common cause of non-leukemia mortality [1, 2]. It is 
proved that increasing the level of ferritin at each 500 ng/ml increases mortality by 36 % [3].
With the advent of new drugs, the view on the problem of treatment of MDS has changed. 
In modern haematology therapeutic approaches in such patients are differentiated and depend on 
the age of patients, general condition, the presence of concomitant pathology and the possibility 
of alloHTC. So in patients with low risk MDS, the main goal of therapy is to reduce the number 
of blood transfusion and improve the quality of life of the patient [4, 5]. Instead, with the more ag-
gressive subtypes of MDS, the end point is to reduce the risk of transformation into acute myeloid 
leukaemia (AML) and to lengthen the duration of overall survival [6].




In order to find the “golden standard” for MDS treatment was urgent the study of the effec-
tiveness of pathogenetic-directed therapy with the help of hypomethylating agents (decitabine (DAC), 
azacitidine (AZA)), registered by the Ministry of Food and Drug Administration, USA (FDA ) for 
clinical use in 2004 and 2006, respectively.
By studying the pathogenetic mechanisms of the formation of MDS, an increase in the 
methylation of the p15IN4B gene encoding the protein-inhibitor of cyclin-dependent kinases 4 and 
6 in this pathology was detected [7]. Hypermethylating of this gene was observed in about 50 % 
of cases, with a higher incidence in patients with subtypes of the refractory anaemia with excess 
blasts (RAЕB) [8, 9]. Inactivation of DNA-methyltransferases leads to the restoration of the imbal-
ance of silent genes and impaired cell differentiation in this nosology [10]. 
2. Aim of the research
Obtain new information on the use of hypomethylating agents (decitabine and azacitidine) 
in treating patients with different degrees of myelodysplastic syndrome according to IPSS.
3. Materials and methods
The article analyzes 41 scientific publications for the period 2012–2017, in which informa-
tion on the effectiveness of hypomethylating agents in patients with myelodysplastic syndrome is 
presented.
4. Result
Azacitidine in the treatment of low risk and high risk MDS according to IPSS. According to 
NCCNV2.2017 recommendations [11] for patients with MDS low and intermediate-1 risk, accord-
ing to IPSS, this therapy is used:
– patients with endogenous erythropoietin (EPO) less than 500 mU/ml in the ineffectiveness 
of therapy with recombinant human erythropoietin (rHu Epo) in monotherapy or in combination 
with granulocyte colony-stimulating factor [12];
– patients with an EPO level above 500 mU/ml in the presence of adverse signs of response 
to immunosuppressive therapy with cyclosporine or antithymocyte globulin (ATG);
– patients with clinically significant thrombocytopenia and/or neutropenia.
It has been shown that hypomethylating agents, in particular AZA, prolong the surviv-
al of patients, regardless of age, FAB or WHO subtype of the disease, the percentage of blast 
and karyotype (although some researchers have noted a better result in patients with the presence 
of –7/del7q) [13], significantly lower the risk of transformation in the AML, and not only reduce the 
transfusion dependence of patients, but also prolong the duration of the response in the previously 
treated patients [14, 15].
According to the NCCN standards for high risk MDS patients (intermediate-2/high IPSS- 
scale risk), intensive chemotherapy followed by HTC is a priority treatment. However, in the ab-
sence of a donor or the impossibility of conducting this procedure (late age of patients, the presence 
of concomitant pathology) by the standard of treatment until recently was the use of hypomethyl-
ating agents, as the first line of therapy in this cohort of patients [11, 16]. In connection with the 
expansion of knowledge about their mechanism of action and side effects, indications for the use of 
this group of drugs have become wider today. Thus, a group of British researchers led by Craddock 
believe that AZA may be the drug of choice for the treatment of recurrences after an unsuccessful 
transplant, resulting in not only a satisfactory response in the fourth part of the treatment (15 % 
confirmed complete remission), but also lengthening the duration of 2 years of survival until 
48 % vs. 12 % for the general population [17, 18]. No less interesting is the study on the use of AZA 
as a supportive therapy after a transplant. After 4-courses AZA at a dose of 32 mg/m2 for 5 days, an 
extension of the duration of not only general, but also leukaemia free survival in these patients was 
noted [19, 20]. A group of researchers from Lebanon in 2014 not only confirmed the above results, 
but also found that AZA is more effective in the presence of a normal diploid karyotype, which in 
some way denies other literature on good performance in patients with chromosome 7 monosomy. 




Despite the contradictions in the effectiveness of the results azacitidine with an abnormal karyo-
type, the question remains interesting and requires a deeper analysis.
Satisfactory results of therapy with hypomethylating agents have become the impetus for 
further study of their effectiveness in patients with MDS of various prognostic subtypes. In 2011, 
phase III data from the randomized trial of CALGB-9221 (Cancer and Leukemia Group B), sub-
cutaneous administration of AZA (75 mg/m2/day, 1–7 days, every 28 days, n=99), were reported 
against the best supportive care (BSC) (n=92) in patients of all MDS subtypes according to the FAB 
classification, which showed significantly higher rates of response to treatment AZA 60 % vs. 5 % 
with traditional therapy (p<0.001). The time to progression or death was statistically longer in the 
azacitidine group compared to the comparative branch: 21 months against 13 months, accordin-
ly (p<0.007). The number of treated, who progressed was significantly higher in the comparison 
group of 38 % versus 15 %, respectively (p <0.001). The median time to reaching the best response 
was 64 and 93 days with AZA and BSC, respectively. However, no significant difference was found 
in the overall survival time of these patients, 20 months against 14 months (p=0.1), since according 
to the protocol after 4 months treatment with the best concomitant therapy patients received further 
treatment with azacitidine. In all of the subjects receiving the hypomethylating agent, the quality 
of life improved, fatigue, shortness of breath were reduced and physical activity increased [11, 21].
No less interesting are the results of the phase III, international, multicenter, randomized, 
AZA-001 trial with subcutaneous administration of AZA in dose 75 mg/m2/day for 1-7 days in 
a 28-day cycle in 179 MDS intermediate-2/high risk patients versus conventional care regimens 
(CCR) that included substitution therapy (105 patients), low-dose AraC (49 patients) and intensive 
chemotherapy (25 patients). Not only the higher percentage of the hematologic response (p=0.0001) 
was established according to the IWG 2000 criteria, but also the longer duration of the overall (24.5 
months versus 15 months, p=0.0001) and the two-year survival (50.8 % vs. 26.2 %, p<0.0001) with 
azacitidine versus induction/consolidation therapy. The duration of the response in the azacitidine 
branch was also significantly longer than 13.6 months against 5.2 months in the comparison group 
(p=0.0002). AZA significantly increased the time to transformation in AML (18.7 months versus 
11.5 months, p<0.001) and decreased dependence on transfusion in 45 % of transfusion dependent 
patients versus 11.4 % in group comparison. Interesting the fact that the hypomethylating agent was 
significantly more effective in patients with unfavorable cytogenetic aberrations, in particular at 
–7/del (7q), in which the duration was significantly longer than the overall survival (13.1 months vs. 
4.6 months, p=0.00001) and leukemia free survival (17.8 months vs. 11.5 months, p<0.0001) [22].
The satisfactory response to AZA therapy has led to the study of alternative doses and treat-
ment regimens for patients. 
– 75 mg/m2/day subcutaneously according to the scheme “5-2-2” every 28 days;
– 50 mg/m2/day subcutaneously according to the scheme “5-2-5” every 28 days;
– 75 mg/m2/day subcutaneously for 5 days every 28 days.
When comparing the results of 5 days the hematological improvement was achieved in 
44 %, 45 % and 56 % of cases with AZA 5-2-2, AZA 5-2-5, and AZA-5, respectively. All three 
alternative regimes provided the development of independence from transfusion in 50 %, 55 % and 
64 % of treated patients, respectively. The percentage of complications was less pronounced at the 
5-day regimen of 75 mg/m2/day, which was 58 % compared with 84 % under the scheme 5-2-2 and 
77 % 5-2-5, This scheme may be recommended for use in ambulatory conditions [23, 24].
At this stage, the II-III phase of the study, the tablet form of azacitidine СС-486, focuses 
on patients with MDS (both primary and pre-treated), with chronic myelomonocytic leukemia and 
AML [25].
The design of the study was as follows (Fig. 1).
In 2015, the first results of I phase of the study are published. It was found that the study drug 
has high stability, good bioavailability and a longer half-life than the subcutaneous administration 
of the drug. Combined mode contributed to a better response of 73 % versus 42 % when using only 
the tablet form. Among the major complications most often encountered during therapy, except for 
febrile neutropenia were gastrointestinal disorders [25].




Fig. 1. AZAPHUS 2007 CL005, phase 1 study of the azacitidine tablet form (CC-486) in patients 
with MDS, CMML, and AML
In connection with the revealed pharmacokinetic properties of SS-486, researchers be-
lieve that prolonged use of the drug may be effective in patients with thrombocytopenia or 
transfusion dependent anaemia, which is confirmed by the clinical study of the III phase of the 
QUAZAR low risk MDS protocol AZA-MDS-003 [26] or prolong the response in the period 
after transplantation – I/II phase of the study CC-486-AML-002 [27].
Decitabine in low and high risk MDS therapy. Decitabine (DAC), which appeared in the 
Ukrainian market in 2008, is also effective in treating MDS.
Dosage questions and DAC injection modes are investigated on a permanent basis. De-
scribed in the literature, the efficacy of maximum single dose doses of 300–500 mg/m2 and modes 
of long 72-hour infusion of small doses (total dose 125–225 mg/m2) at intervals of 6 weeks did not 
meet the expectations of scientists, because such therapy was accompanied by pronounced cytope-
nic states, the severity of which was higher than the result obtained, in this connection, the schemes 
are practically not used in modern practice.
North American researchers presented the results of a multicenter phase III study to eval-
uate the effectiveness of DAC (15 mg/m2/h for 3 hours every 8 hours 1–3 days every 6 weeks) 
compared with the best concomitant therapy in elderly patients with primary or secondary MDS. 
The use of this regimen did not show a significant difference in the duration of overall survival of 
patients compared with the control group, however, it prolonged the median time before transfor-
mation or death (12 months versus 6.8 months, p=0.03). The response rate for treatment was fairly 
low and reached 17 [11].
In 2005, Kantarjian et al presented the results of the Anderson Cancer Cente study, which 
evaluated the effectiveness of DAC in three regimens: 10 mg/m2 intravenous 10 days, 20 mg/m2 
5 days and 20 mg/m2 subcutaneous 5 days at intervals between courses 4 weeks. The complete 
remission of the 5-day regimen in the form of proven infusion was the highest and was 39 % versus 
21 % for subcutaneous administration and 24 % for the 10-day regimen, whereby the 5-day intra-
venous regimen was considered to be the most optimal for use [28].
Instead, newer studies comparing 3-day treatment with 15 mg/m2 three times a day and 
a 5-day regimen at 20 mg/m2/day showed a higher percentage of overall response rate when 
using the 3-day regimen (29.4 % vs. 25, 5 % in the comparison group), however, no difference 
was found in the hematological improvement and the leukemia free survival. Side effects as-
sociated with myelosuppression (85.6 %) and infections (43.2 %) were also not significantly 
different [29, 30].
Regardless, a group of German researchers analyzed the 5-day regimen of using 20 mg/m2 
doses of decibitin IV as compared with concomitant therapy in older patients with intermediate or 
high risk MDS versus indications for intensive chemotherapy. Median survival without progres-
 




sion was significantly longer in patients treated with decitabine 6.6 months against 3.0 months 
(p=0.004), and the risk of transformation during the year in these patients was significantly lower 
(22 % vs. 33 %, p=0.036). At the same time, the two study groups did not find a significant differ-
ence in the duration of overall survival (10.1 months versus 8.5 months, p=0.38) and the leukemia 
free survival (8.8 months versus 6.1 months, p=0.38). In the DAC branch, complete and partial 
remission was observed at 13 % and 6 %, respectively, with additional hematologic improvement 
in 15 % of patients relative to the IWG 2006 criteria, with a 2 % hematological improvement in the 
adjunctive therapy line with no hematologic response [21]. 
Differentiated efficacy of azacitidine and decitabine in the treatment of MDS. In 2013 was 
published a study that aimed to directly compare the efficacy and safety of azacytidine and decit-
abine Among the 300 treated patients, of whom 203 received azacitidine and 97 decitabine, no sig-
nificant difference was found in the overall response (44 % vs. 52 %), overall survival (26 months 
versus 22.9 months) and survival rate of leukemia (7.7 vs. 7.0 months), and in particular in the 
number of transformed patients per year (16 % vs. 22 %). It was interesting to note the fact that 
the age-related survival rate was significant: in patients older than 65 years, the survival rate was 
significantly longer in the azatsitydine group (HR 3; 95 % CI 1.22-7.37; p=0.017), with the same 
difference in the group of subjects under 65 years old not statistically significant (HR 1.17; 95 % CI 
0.54–2.54; p=0.7). Instead, the development of severe cytopenia and infectious complications was 
significantly higher in the group treated with decitabine [31].
Interesting and rather contradictory are the results of the phase II study of the safety and 
efficacy of the use of small doses of decitabine in comparison with low doses of azacytidine in a 
group of low-risk MDS patients receiving intravenous/subcutaneously azacitidine 75 mg/m2 daily 
or 20 mg/m2 of decitabine daily intravenously 3 consecutive days in a 28-day cycle. It was found 
that the percentage of patients who responded to treatment (70 % vs. 49 %, p=0.03) and those who 
observed the development of transfusional independence (32 % vs. 16 %, p=0.02) was significant-
ly higher when using decitabine. The cytogenetic response rates were 61 % and 25 % (p=0.02), 
respectively, including the duration of leukemia free survival which was longer in the decitabine 
20 months versus 13 months for azacitidine [32].
Recent publications on the MDS Clinical Research Consortium have demonstrated a su-
perior response in female patients with decitabine compared with azacitidine, but with a longer 
survival in patients treated with azacitidine (21.1 months versus 13.2 months, p=0.0014). The 
reasons for this difference, according to the authors, may be differences in the pharmacoki-
netics of drugs in women and men [33]. Other studies show the dependence of the response 
to treatment with hypomethylating agents on peripheral blood parameters. In particular, the 
platelet count ≥100×109/l (p=0.007) and the leukocyte count <3.0×109/l (p=0.03) are considered 
to be favorable predictors of the likelihood of a satisfactory response to therapy. Additionally, 
it has been established that the lack of cytogenetic changes or the presence of favorable cyto-
genetic aberrations significantly increases the likelihood of a satisfactory response to treat-
ment [34]. Instead, Bejaretal found that the presence of TET2 and DNMT3A mutations doubly 
increases the likelihood of receiving response to therapy [35]. However, the mutation status 
is not associated with the duration of the response received or the improvement of survival in 
any of the studies.
The presence of numerous genetic and epigenetic mechanisms underlying MDS has led to 
the use of combinations of drugs with different application points. Thus, with a combination of 
lenalidomide and azacitidine, the response to treatment is increased to 69 % versus 56 % when 
monotherapy azacitidine is used in patients with high risk MDS. Instead, such a combination is 
not associated with prolonged leukaemia free survival where its duration is 18.8 months against 
33.2 months with monotherapy [36].
At the study stage, a combination of azacitidine with etanercept or vorinostat in patients 
with high risk MDS, which showed a high response rate of 72 % for the first combination and 82 % 
for another [37], a combination of histone deacetylase inhibitors (panobinostat) and azacitidine also 
showed a higher percentage of response, 27.5 % vs. 14.3 %, no difference was found in the duration 




of overall survival (70 % vs. 60 % in mono-regimens), and the percentage of complications was 
significantly higher in the combined regimen [38].
No less striking were the results (phase II) of the use of the azacitidine scheme with the 
monoclonal antibody, gemtuzumab, in combination with hydroxyurea. Accordingly, response was 
received in 70 % of the patients with high risk MDS. The overall survival time for these patients 
was 10 months, and the response achieved was at least 8 months. [39].
Despite the fact that hypomethylating agents significantly improve the treatment outcome in 
patients with MDS, only half of the patients receive an objective response, and most respondents 
lose it within 1–2 years. The genesis of primary and secondary resistance to hypomethylating 
therapy is not established, and the failure of therapy is associated with a very poor prognosis in 
MDS patients of both low and high risk of transformation in the AML [40]. The overall survival 
rate in patients with high risk MDS after failure of therapy with azacitidine or decitabine is 5.6 and 
4.3 months respectively [41]. In a report by the Moffitt group, the overall survival time after ineffec-
tiveness of azacitidine, analyzed in 280 patients with low-risk MDS, was 18.5 months (95 % confi-
dence interval, 13.5–23.5 months), and decreased in patients with intermediate risk MDS according 
to IPSS down to 15 months [14]. Another retrospective analysis of 59 patients with IPSS low risk 
MDS with primary or secondary azacitidine ineffectiveness showed similarly low overall survival 
rates in these patients – 16.7 months. [37]. The median of the overall survival of 74 patients with 
secondary AL after failure of azacitidine was even lower and was 3.4 months with a probability of 
1 year survival of only 8 % [41]. 
5. Discussion
After analyzing the effectiveness of the use of hypomethylating mediators in patients with 
MDS, we can talk about a significant progress in the treatment of this pathology after the intro-
duction of pathogenetic therapy, and in particular, the hypomethylating drugs. In view of the im-
possibility of fully curing these patients because of the limitations in the allogeneic hematopoietic 
stem cells transplantation, the use of drugs of this subgroup, according to most authors, not only 
improves the quality of life, but significantly lengthens the duration of both overall and leukaemia 
free survival, in particular in patients with high risk MDS.
Expansion of indications for the use of these drugs in patients after transplantation in order 
to lengthen the duration of remission achieved, looks like another promising direction of therapeu-
tic tactics for this group of patients.
Although most authors point to a relatively high incidence of complications that develop 
with the use of hypomethylating agents, the constant process of hypermethylation of DNA in the 
MDS necessitates their continued use until the progression of the disease or unacceptable toxicity.
The development of resistance to this type of treatment contributed to the further search for 
new schemes based on a combination of drugs of different pathogenetic orientation and it is the 
nearest prospect of the treatment of MDS of various FAB subtypes.
6. Conclusion
1. An analysis of literature sources has shown higher efficacy of hypomethylating agents 
compared to the best supportive care or other standard treatment regimens in low and high risk 
MDS patients.
2. The absence of significant differences in the overall survival and leukemia free survival, 
the percentage of response and reduction of transfusion dependence, as well as the number of trans-
formed patients during the year when using azacitidine and decitabine, suggests the use of both 
hypomethylating agents for the treatment of all subtypes of MDS.
3. In low-risk and high-risk patients with MDS over 65 years of age a drug of choice is 
azacitidine, since when used in this cohort, respondents have significantly higher survival rates 
and significantly lower incidence of severe cytopenia and infectious complications compared with 
the use of decitabine. In younger patients, this trend was statistically insignificant and the drug of 
choice for them may be as azaсitidine and decitabine.




4. The nearest prospect of treatment of myelodysplastic syndrome is the creation of new 
treatment regimens based on a combination of drugs of different pathogenetic direction.
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